HEAD-TO-HEAD COMPARISON
Mounjaro vs OzempicTirzepatide vs Semaglutide
Verdict: Mounjaro (tirzepatide) is a dual GIP / GLP-1 receptor agonist; Ozempic (semaglutide) is a GLP-1 mono-agonist. In head-to-head and indirect-comparison data, tirzepatide produces larger mean weight loss and stronger HbA1c reduction at maintenance dose. Ozempic has a longer real-world track record and broader insurance coverage in some plans.
Side-by-side comparison
| Mounjaro | Ozempic | |
|---|---|---|
| Active ingredient | Tirzepatide | Semaglutide |
| Manufacturer | Eli Lilly | Novo Nordisk |
| FDA approval | 2022 | 2017 |
| Indication | Type 2 diabetes glycemic control | Type 2 diabetes glycemic control and CV risk reduction in T2D with established CV disease |
| Starting dose | Step 1 of 6 | Step 1 of 4 |
| Maintenance target | 15 mg/week | 2 mg/week |
| Titration length | ~21 weeks | ~16 weeks |
| Mean weight loss | ~15 to 20% mean (off-label / secondary endpoint) | ~10 to 12% mean (secondary endpoint) |
| HbA1c reduction | 2.0 to 2.5 pp (SURPASS) | 1.5 to 1.8 pp (SUSTAIN) |
| Cost (US list) | ~$1,000 / mo US list | ~$900 / mo US list |
| Insurance | T2D indication usually covered | T2D indication usually covered |
Who should pick which
- Pick Mounjaro if the primary clinical goal is glycemic control in Type 2 diabetes; the FDA indication aligns and insurance coverage is more reliable.
- Consider Mounjaro (tirzepatide) if mean weight loss in published trials is the deciding factor. Dual GIP + GLP-1 mechanism produces the largest effect size in head-to-head data.
- Consider Mounjaro for type 2 diabetes use cases; titration completes in roughly 21 weeks.
- Consider Ozempic for type 2 diabetes use cases; titration completes in roughly 16 weeks.
Switching between the two
Transitioning between tirzepatide and semaglutide typically restarts titration at the new product's starting dose to manage tolerability. Some clinicians use a one-step-down approach if the prior agent was at maintenance.
Open Tirzepatide Dose Calculator → Compare full titration schedules side by sideFrequently asked
Is Mounjaro better than Ozempic?
Mounjaro (tirzepatide) is a dual GIP / GLP-1 receptor agonist; Ozempic (semaglutide) is a GLP-1 mono-agonist. In head-to-head and indirect-comparison data, tirzepatide produces larger mean weight loss and stronger HbA1c reduction at maintenance dose. Ozempic has a longer real-world track record and broader insurance coverage in some plans.
Can I switch from Mounjaro to Ozempic?
Transitioning between tirzepatide and semaglutide typically restarts titration at the new product's starting dose to manage tolerability. Some clinicians use a one-step-down approach if the prior agent was at maintenance.
Does Mounjaro produce more weight loss than Ozempic?
Mounjaro: ~15 to 20% mean (off-label / secondary endpoint). Ozempic: ~10 to 12% mean (secondary endpoint). Direct comparisons depend on dose, duration, and population studied; check the linked trial citations on each brand page for full context.
Why is Mounjaro priced differently from Ozempic?
Mounjaro costs ~$1,000 / mo US list; Ozempic costs ~$900 / mo US list. Differences reflect manufacturer pricing strategy, FDA indication (obesity-labeled brands often face patchier insurance coverage than diabetes-labeled brands), and whether the product is a finished drug or a pharmacy compound.
Which is better for Type 2 diabetes, Mounjaro or Ozempic?
Both Mounjaro and Ozempic address T2D-relevant pathways via GLP-1 receptor activity. Trial HbA1c reductions: Mounjaro 2.0 to 2.5 pp (SURPASS); Ozempic 1.5 to 1.8 pp (SUSTAIN).
Related
For research informational use only. Not medical advice. Mounjaro is a registered trademark of its manufacturer. Consult a qualified healthcare provider for clinical decisions.